Business
Perimeter Announces B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Accepted for Presentation at the 2025 Annual Meeting of the American Society of Breast Surgeons
Perimeter Announces B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Accepted for Presentation at...
About this update from Perimeter Medical Imaging Ai Inc
[{"type":"text","content":"\n\n\n\n Perimeter Announces B-Series OCT with ImgAssist AI 2.0 Pivotal Trial Accepted for Presentation at the 2025 Annual Meeting of the American Society of Breast Surgeons\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n\n\n\n\n\n – Pivotal trial met its primary endpoint with statistically significant reduction in patients with residual cancer during surgery (p-value = 0.0050) –\n \n\n\n\n – Presentation will highlight both previously reported positive topline results and new additional analyses, including secondary endpoints and additional reporting –\n \n\n\n\n\n TORONTO\n \n and\n \n DALLAS\n \n\n ,\n \n\n March 5, 2025\n \n\n /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (\"Perimeter\" or the \"Company\"), a commercial-stage medical technology company, is pleased to announce that detailed results from the pivotal trial evaluating the use of its next-generation B-Series OCT with ImgAssist AI 2.0 (\"Perimeter B-Series\") during breast-conserving surgeries (\"BCS\") will be presented during the scientific session of the\n \n 26\n \n th\n \n Annual Meeting of the American Society of Breast Surgeons\n \n (\"ASBrS\") taking place in\n \n Las Vegas, NV\n \n ,\n \n April 30-May 4, 2025\n \n .\n \n\n ASBrS is the primary leadership organization for general surgeons who treat patients with breast disease and is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients.\n \n\n The detailed results of the Perimeter B-Series pivotal trial are subject to an embargo policy, pursuant to which all scientific abstracts accepted for oral or poster presentations during the ASBrS 26th Annual Meeting, press releases, and the Society's Official Proceedings are embargoed until\n \n 1:00 pm PST\n \n on\n \n May 1, 2025\n \n . The full abstract will be published by the\n \n Annals of Surgical Oncology\n \n and released following the oral presentation by Dr.\...